Related Experiment Videos
Autoimmune diabetes and its antigenic triggers
1Department of Microbiology and Immunology, Stanford University School of Medicine, USA.
Hospital Practice (1995)
|July 15, 1995
Summary
Alterations in HLA genes influence susceptibility to insulin-dependent diseases. Glutamic acid decarboxylase-65 (GAD-65) is a key trigger, and its experimental administration can delay disease by reducing autoimmune responses.
Area of Science:
- Immunology
- Genetics
- Endocrinology
Background:
- Susceptibility to insulin-dependent diseases is strongly linked to human leukocyte antigen (HLA) gene variations.
- Several autoantigenic triggers contribute to disease development, alongside insulin itself.
Purpose of the Study:
- To investigate the role of glutamic acid decarboxylase-65 (GAD-65) as a primary autoantigenic trigger in insulin-dependent diseases.
- To explore the therapeutic potential of GAD-65 modulation in autoimmune responses.
Main Methods:
- Experimental administration of GAD-65 via intrathymic or intravenous injection in relevant models.
- Assessment of autoimmune response modulation and disease progression following GAD-65 administration.
Main Results:
- Glutamic acid decarboxylase-65 (GAD-65) is identified as a significant autoantigenic trigger.
- Intrathymic or intravenous GAD-65 injection demonstrated a dampening effect on the autoimmune response.
Conclusions:
- GAD-65 plays a crucial role in the pathogenesis of insulin-dependent diseases.
- GAD-65 administration shows promise as a future therapeutic strategy for delaying disease onset and progression.